

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC., CELLTRION, INC., and
APOTEX, INC.,
Petitioners

v.

REGENERON PHARMACEUTICALS, INC.,
Patent Owner

Case IPR2021-00881¹
Patent No. 9,254,338 B2

EXPERT DECLARATION OF RICHARD MANNING, PH.D.

CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER

¹ IPR2022-00258 and IPR2022-00298 have been joined with this proceeding.

Summary of Contents

1. Introduction 1

2. Regeneron Pharmaceuticals, Inc. 8

3. U.S. Patent No. 9,254,338..... 10

4. Relevant Economic Principles 14

5. Medical Conditions at Issue 17

6. Overview of Treatment Options for Relevant Angiogenic Eye Disorders 24

7. Medicare Part B Reimbursement Policy 43

8. Commercial Success 52

9. Dosing Regimen is an Important Driver of Demand for Eylea 97

10. Eylea’s Commercial Success Cannot be Explained by Factors Not Related to the Claimed Methods of Treatment 122

Table of Contents

1. Introduction 1

 1.1. Qualifications..... 1

 1.2. Scope of work..... 3

 1.3. Framework for commercial success 4

2. Regeneron Pharmaceuticals, Inc. 8

3. U.S. Patent No. 9,254,338..... 10

4. Relevant Economic Principles 14

5. Medical Conditions at Issue 17

6. Overview of Treatment Options for Relevant Angiogenic Eye Disorders 24

 6.1. Laser-based treatment options available prior to anti-VEGF therapies..... 24

 6.2. Anti-VEGF treatment options 26

 6.2.1. Macugen 27

 6.2.2. Avastin..... 28

 6.2.3. Lucentis 29

 6.2.4. Eylea 31

 6.2.5. Beovu..... 34

 6.2.6. FDA approvals for anti-VEGF treatments 38

 6.2.7. FDA-approved dosing schedules for anti-VEGF treatment options 39

7. Medicare Part B Reimbursement Policy 43

8. Commercial Success 52

 8.1. U.S. Eylea sales and revenue..... 52

 8.1.1. Gross sales 53

 8.1.2. Net sales 54

 8.2. U.S. Eylea profits..... 56

 8.3. Eylea’s share of anti-VEGF sales..... 60

 8.3.1. Data sources 61

 Medicare Part B services and procedures 61

CONFIDENTIAL MATERIAL– SUBJECT TO PROTECTIVE ORDER

Vestrum Health	64
Regeneron ATU surveys	66
8.3.2. Eylea’s historic patient share as an indicator of commercial success	69
8.3.3. Eylea’s displacement of other anti-VEGF treatments as an indicator of commercial success.....	80
8.3.4. Eylea status as physicians’ most used treatment.....	86
8.4. Price has not hindered Eylea’s commercial success	89
9. Dosing Regimen is an Important Driver of Demand for Eylea	97
9.1. Eylea’s patented dosing regimen addressed an unmet need for longer dosing intervals	99
9.2. Eylea’s patented dosing regimen is a key differentiating factor ..	103
9.2.1. Regeneron has promoted the patented dosing schedule and credits it as a key factor causing commercial success	104
9.2.2. Regeneron ATU surveys show that dosing interval has been an important driver of Eylea prescribing.....	109
9.2.3. Members of the ASRS identified Eylea as allowing the longest treatment interval	114
9.2.4. Regeneron public statements demonstrate the importance of the patented dosing schedule to Eylea’s commercial success	117
9.3. Eylea is more effective at treating patients with worse visual acuity, which imparts a downward bias to its observed treatment interval	118
10. Eylea’s Commercial Success Cannot be Explained by Factors Not Related to the Claimed Methods of Treatment	122
10.1. Regeneron’s marketing efforts have been limited and have included promotion of the patented dosing regimen	122
10.2. Regeneron has had limited discounting and rebate programs.....	126
10.3. Regeneron’s sampling program is unlikely to have driven Eylea’s commercial success	129

Table of Attachments

<u>Section A</u>	<u>Expert Materials</u>
Attachment A-1	Curriculum Vitae of Richard Manning, Ph.D.
<u>Section B</u>	<u>Dosing Directions</u>
Attachment B-1	Dosing Directions on FDA Labels
<u>Section C</u>	<u>Sales Shares</u>
Attachment C-1	Sales Share Summary - All Indications
Attachment C-2	Sales Share Summary - Wet AMD
Attachment C-3	Sales Share Summary - DME
Attachment C-4	Sales Share Summary - DR without DME
Attachment C-5	Sales Share Summary - RVO
Attachment C-6	Eylea's Sales Share Across Different Data Sources - All Indications
Attachment C-7	Eylea's Sales Share Across Different Data Sources - Wet AMD
Attachment C-8	Eylea's Sales Share Across Different Data Sources - DME
Attachment C-9	Eylea's Sales Share Across Different Data Sources - DR without DME
Attachment C-10	Eylea's Sales Share Across Different Data Sources - RVO
Attachment C-11	Percentage Point Change in Total Sales Share Since Eylea Launch – ATU Data
Attachment C-12	Percentage Point Change in Total Sales Share Since Eylea Launch – Medicare Part B Data

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.